<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321256</url>
  </required_header>
  <id_info>
    <org_study_id>011226/DGS-2001/0195</org_study_id>
    <nct_id>NCT00321256</nct_id>
  </id_info>
  <brief_title>Human Islet Transplantation in Brittle Type 1 Diabetes Mellitus. The GRAGIL 2 Study.</brief_title>
  <official_title>Transplantation d'Ilots Pancreatiques Allogeniques Adultes Pour le Traitement du Diabete Insulino-dependant: Etude GRAGIL 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alfediam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <brief_summary>
    <textblock>
      This research project is supported by a multicentric network of collaborators whose goal is
      to assess the efficacy of transplanting allogenic pancreas islets to restore insulin
      secretion in patients with brittle type 1, insulin-dependent diabetes mellitus and to improve
      their metabolic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The general objective is to demonstrate the beneficial effect of islet allotransplantation in
      patients with brittle type 1 diabetes with no endogenous insulin secretion, for whom the risk
      of the spontaneous course of the disease is judged to be worse than the
      transplantation-related risk. The specific objective is to establish reference data for islet
      transplantation in non-uremic patients with brittle diabetes, in a multicentric network
      setting, using the Edmonton protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of insulin-independence, judged upon the following criteria : HbA1c &lt; 6.1%,</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>post-prandial blood glucose &lt; 180 mg/dl, mean amplitude of glycemic excursion (MAGE index)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>&lt; 60 mg/dl, basal C-peptide &gt; 0.5 ng/ml. This insulin independent rate will be assessed 6 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>and 12 months following transplantation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of success according to the DiaCell composite score defined by the following 4 items : functional islet graft, defined by a basal C-peptide &gt; 0.5 ng/ml;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>good metabolic control, defined by HbA1c ≤ 6.5%; disappearance of hypoglycemic events; reduction in exogenous insulin needs ≥ 30%.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and quality of life will also be assessed.</measure>
  </secondary_outcome>
  <enrollment>22</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>human pancreatic islet transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 1 diabetes mellitus

          -  Disease duration &gt; 5 years

          -  Despite intensive insulin therapy with tight endocrinologist supervision, persistence
             of the following conditions : hypoglycemia unawareness (&lt; 54 mg/dl) ; brittleness with
             at least two episodes of severe hypoglycemia ((defined by the need for assistance to
             correct the blood glucose level) or ketoacidosis per year , or often enough that the
             diabetologist judges the frequency to be life-threatening, the risk of transplantation
             and immunosuppression being judged to be less than the risk of the spontaneous course
             of uncontrolled diabetes

          -  Basal and stimulated plasma C-peptide &lt; 0.2 ng/ml

          -  Creatinine clearance ≥ 50 ml/min/1.73 m2 and proteinuria &lt; 0.5 g/24h

        Exclusion criteria:

          -  Severe cardiovascular disease (recent myocardial infarction, unstable coronaropathy…)

          -  Severe systemic infection, including hepatitis C or B viral infection, HIV infection
             or tuberculosis

          -  Past or present neoplasia (with the exception of non melanoma skin cancers)

          -  Body weight &gt; 70 kg in women and BW &gt; 75 kg in men or BMI &gt; 26

          -  Stimulated C-peptide ≥ 0.3 ng/ml upon Glucagon or Arginine stimulation

          -  Age &lt; 18 years or &gt; 65 years

          -  Creatinine clearance &lt; 50 ml/min/1.73 m2

          -  Albuminuria &gt; 300 mg /24h or proteinuria &gt; 0.5 g/24h

          -  Hemoglobinemia &lt; 120 g/l in women or &lt; 130 g/l in men

          -  Liver disease (enzymes &gt; 1.5 N) such as cirrhosis or hepatitis

          -  Liver hemangioma

          -  Untreated proliferating diabetic retinopathy

          -  Pregnancy, lactation, pregnancy project or absence of efficient contraception

          -  Previous transplantation or immunization as judged by anti-HLA antibodies (&gt; 20%)

          -  Insulin needs &gt; 0.7 IU/kg/d or &gt; 50 IU

          -  HbA1c &gt; 12 %

          -  Any medical condition needing the chronic use of steroids

          -  Addison disease

          -  Any hemostasis disorder needing a prolonged treatment with anticoagulation drugs.
             Low-dose aspirin is permitted. coagulation disorders contraindicating the procedure,
             such as platelet count &lt; 100000/mm3.

          -  Serious life-threatening disease

          -  Medical or surgical history potentially influencing the absorption, distribution,
             metabolism and clearance of drugs

          -  Uncontrolled hypercholesterolemia (&gt; 350 mg/dl, 9.1 mmol/l) or hypertriglyceridemia (&gt;
             500 mg/dl, 5.6 mmol/l)

          -  Leukocytes &lt; 4500/mm3, neutrophils &lt; 2000/mm3, platelets &lt; 100000/mm3

          -  Any medical or psychosocial condition susceptible to interfere with the study, such as
             drug abuse or recent alcohol abuse

          -  Poor therapeutic observance

          -  Failure to communicate or cooperate with the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Y Benhamou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universty Hospital, Grenoble, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Morel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Geneva, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Thivolet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfred Penfornis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Besancon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Kessler, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Renard, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel Badet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyrille Colin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Berney, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Geneva, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Strasbourg</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Surgery</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <keyword>islet transplantation</keyword>
  <keyword>brittle diabetes</keyword>
  <keyword>severe hypoglycemia</keyword>
  <keyword>type 1 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

